Diabetes is one of the top ten diseases that causes death, and it has become a major concern in many countries, with type 2 diabetes accounting for 96% of diabetes cases. The progression of type 2 diabetes to neuropathy is a complex process influenced by various factors, including glycemic control, duration of diabetes, and individual characteristics. Absorbing chains are one of the applications of Markov chains, which are used to determine how long patients remain in a transient state before they are absorbed. The study objective was to predict the mean sojourn time (average time) that type 2 diabetic patients live with the disease before they enter the absorbed state (i.e., amputation of the limbs or death). Fasting blood sugar levels and neuropathy conditions developed by type 2 diabetic patients were divided into eight states. The states were further classified into transient and absorbing states, where States 1-6 (low FBS, normal FBS, moderate FBS, high FBS, and numbness) formed transient states, and States 7 and 8 were absorbing states (amputation of limbs and death). The results revealed that the average time for patients with a low FBS state to stay with the disease before their limbs are amputated or to die is 14 years, and the average time for those with normal and moderate FBS states is 27 years each. Patients in the high and numbness states have average stay times of 26 and 23 years, respectively, to live with the disease before their limbs are amputated or they die. However, patients in the ulcer state have an average of two years to live with the disease before their limbs are amputated or die. In conclusion, patients’ condition deteriorates gradually as they transition to the complication stage, and patients are more likely to have their limbs amputated or die.
| Published in | Biomedical Statistics and Informatics (Volume 11, Issue 1) |
| DOI | 10.11648/j.bsi.20261101.13 |
| Page(s) | 31-39 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2026. Published by Science Publishing Group |
Markov Chain, Neuropathy, Transition, Fasting Blood Sugar Level, Transient States, Absorbed States
States | Health status | FBS Level/condition |
|---|---|---|
S1 | Low FBS | 3.9 mmol/L |
S2 | Normal FBS | 3.9 - 5.7 mmol/L |
S3 | Moderate FBS | 5.8 - 6.9 mmol/L |
S4 | High FBS | 7.0 mmol/L |
S5 | Numbness | Hyperglycemia |
S6 | Ulcers | Wounds |
S7 | Amputation | Loss of limbs |
S8 | Death | no life |
STATES | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | TOTAL |
|---|---|---|---|---|---|---|---|---|---|
1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 4 |
2 | 1 | 16 | 5 | 6 | 3 | 0 | 0 | 0 | 31 |
3 | 0 | 4 | 0 | 14 | 1 | 0 | 0 | 0 | 19 |
4 | 2 | 9 | 7 | 40 | 3 | 0 | 0 | 2 | 63 |
5 | 0 | 0 | 0 | 5 | 5 | 1 | 0 | 0 | 11 |
6 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
7 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TOTAL | 3 | 30 | 12 | 66 | 12 | 2 | 2 | 4 | 131 |
STATES | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
1 | 0 | 0.25 | 0 | 0.25 | 0 | 0 | 0 | 0.5 |
2 | 0.032 | 0.52 | 0.161 | 0.194 | 0.096 | 0 | 0 | 0 |
3 | 0 | 0.211 | 0 | 0.737 | 0.052 | 0 | 0 | 0 |
4 | 0.032 | 0.142 | 0.111 | 0.635 | 0.047 | 0 | 0 | 0.032 |
5 | 0 | 0 | 0 | 0.455 | 0.454 | 0.091 | 0 | 0 |
6 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 0 |
7 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
|---|---|---|---|---|---|---|---|---|
1 | 0 | 0.25 | 0 | 0.25 | 0 | 0 | 0 | 0.5 |
2 | 0.032 | 0.516 | 0.161 | 0.194 | 0.097 | 0 | 0 | 0 |
3 | 0 | 0.211 | 0 | 0.737 | 0.052 | 0 | 0 | 0 |
4 | 0.032 | 0.143 | 0.111 | 0.635 | 0.048 | 0 | 0 | 0.032 |
5 | 0 | 0 | 0 | 0.455 | 0.455 | 0.090 | 0 | 0 |
6 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 0 |
7 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
AP | Absorption Probability |
DM | Diabetes Mellitus |
EAP | Expected Absorption Probability |
FBS | Fasting Blood Sugar |
SSA | Sub-Saharan Africa |
Mmol/L | Millimole per Litre |
T2DM | Type 2 Diabetes Mellitus |
HbA1c | Hemoglobin A1c |
| [1] | Karamanou M, Protogerou A, Tsoucalas G, Androutsos G, “Milestones in the history of diabetes mellitus: The main contributors.” World J Diabetes, vol. 7(1), pp. 1–7, 2016. |
| [2] | G. Roglic, “Review Article WHO Global report on diabetes : A summary,” pp. 3–8, 2016. |
| [3] | S. Mustapha et al., “PLOS GLOBAL PUBLIC HEALTH Changes in trends and patterns of glycaemic control at Ghana ’ s National Diabetes Management and Research Centre during the era of the COVID-19 pandemic,” vol. 25, pp. 1–19, 2023, |
| [4] | M. L. Doherty, E. Owusu-Dabo, O. S. Kantanka, R. O. Brawer, and J. D. Plumb, “Type 2 diabetes in a rapidly urbanizing region of Ghana, West Africa: A qualitative study of dietary preferences, knowledge and practices,” BMC Public Health, vol. 14, no. 1, pp. 1–8, 2014, |
| [5] | P. N. A.-P. K. A. A. and J. C. M. Motala, “Diabetes in the Africa region,” Diabetes Res. Clin. Pract., vol. 103, pp. 197–205, 2014. |
| [6] | I. Danquah et al., “Diabetes mellitus type 2 in urban Ghana : characteristics and associated factors,” BMC Public Health, vol. 12, no. 1, pp. 210–8, 2012, |
| [7] | S. Abubaker, S. Boatemaa, C. S. Grijalva-Eternod, and K. Adjaye-Gbewonyo, “The contextual awareness, response and evaluation (CARE) diabetes project : study design for a quantitative survey of diabetes prevalence and non-communicable disease risk in Ga Mashie, Accra, Ghana ABSTRACT,” Glob. Health Action, vol. 17, no. 1, 2024, |
| [8] | T. Hormenu et al., “Unmasking the Risk Factors Associated with Undiagnosed Diabetes and Prediabetes in Ghana: Insights from Cardiometabolic Risk (CarMeR) Study-APTI Project,” 2024. |
| [9] | H. Iwasaki, H. Yagyu, and H. Shimano, “A Comprehensive Analysis of Diabetic Complications and,” J Atheroscler Thromb, vol. 32, pp. 550–559, 2025, |
| [10] | M. Alkandari and A. Hollywood, “People ’ s experiences living with peripheral neuropathy : Front. Pain Res., no. June, 2023. |
| [11] | V. Muyambi et al., “Diabetic peripheral neuropathy and associated factors among patients attending Mbarara Regional Referral Hospital, Southwestern Uganda: a cross sctional study,” Discov. Med., 2025, |
| [12] | Y. Yang et al., “Diabetic neuropathy : cutting-edge research and future directions,” Signal Transduct. Target. Ther., no. August 2024, 2025, |
| [13] | H. Amsalu, M. Hailu, A. Asefa, and M. Ayenew, “The effect of lifestyle factors on chronic complications of diabetes at public health hospitals in Southwest Ethiopia,” Sci. Rep., pp. 1–9, 2024, |
| [14] | M. Dubský, D. Sojáková, V. Fejfarová, and E. B. Jude, “Diabetic Peripheral Neuropathy : New Diagnostics and Treatment Perspectives,” Drugs Aging, vol. 43, no. 1, pp. 29–48, 2026, |
| [15] | Y. Wu, Y. Ding, Y. Tanaka, and W. Zhang, “Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention,” International journal of medical sciences, vol. 11, no. 11. pp. 1185–1200, 2014. |
| [16] | P. Srikanth, “Using Markov chains to predict the natural progression of diabetic retinopathy,” Int. J. Ophthalmol., vol. 8, no. 1, pp. 132–137, 2015, |
APA Style
Bayeldeng, G., Amponsah, I. K. V. (2026). Modeling Diabetic Neuropathy in Type 2 Diabetes Patients via the Absorbing Markov Chain in Techiman Municipality, Ghana. Biomedical Statistics and Informatics, 11(1), 31-39. https://doi.org/10.11648/j.bsi.20261101.13
ACS Style
Bayeldeng, G.; Amponsah, I. K. V. Modeling Diabetic Neuropathy in Type 2 Diabetes Patients via the Absorbing Markov Chain in Techiman Municipality, Ghana. Biomed. Stat. Inform. 2026, 11(1), 31-39. doi: 10.11648/j.bsi.20261101.13
@article{10.11648/j.bsi.20261101.13,
author = {Gladys Bayeldeng and Irene Kafui Vorsah Amponsah},
title = {Modeling Diabetic Neuropathy in Type 2 Diabetes Patients via the Absorbing Markov Chain in Techiman Municipality, Ghana},
journal = {Biomedical Statistics and Informatics},
volume = {11},
number = {1},
pages = {31-39},
doi = {10.11648/j.bsi.20261101.13},
url = {https://doi.org/10.11648/j.bsi.20261101.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bsi.20261101.13},
abstract = {Diabetes is one of the top ten diseases that causes death, and it has become a major concern in many countries, with type 2 diabetes accounting for 96% of diabetes cases. The progression of type 2 diabetes to neuropathy is a complex process influenced by various factors, including glycemic control, duration of diabetes, and individual characteristics. Absorbing chains are one of the applications of Markov chains, which are used to determine how long patients remain in a transient state before they are absorbed. The study objective was to predict the mean sojourn time (average time) that type 2 diabetic patients live with the disease before they enter the absorbed state (i.e., amputation of the limbs or death). Fasting blood sugar levels and neuropathy conditions developed by type 2 diabetic patients were divided into eight states. The states were further classified into transient and absorbing states, where States 1-6 (low FBS, normal FBS, moderate FBS, high FBS, and numbness) formed transient states, and States 7 and 8 were absorbing states (amputation of limbs and death). The results revealed that the average time for patients with a low FBS state to stay with the disease before their limbs are amputated or to die is 14 years, and the average time for those with normal and moderate FBS states is 27 years each. Patients in the high and numbness states have average stay times of 26 and 23 years, respectively, to live with the disease before their limbs are amputated or they die. However, patients in the ulcer state have an average of two years to live with the disease before their limbs are amputated or die. In conclusion, patients’ condition deteriorates gradually as they transition to the complication stage, and patients are more likely to have their limbs amputated or die.},
year = {2026}
}
TY - JOUR T1 - Modeling Diabetic Neuropathy in Type 2 Diabetes Patients via the Absorbing Markov Chain in Techiman Municipality, Ghana AU - Gladys Bayeldeng AU - Irene Kafui Vorsah Amponsah Y1 - 2026/03/09 PY - 2026 N1 - https://doi.org/10.11648/j.bsi.20261101.13 DO - 10.11648/j.bsi.20261101.13 T2 - Biomedical Statistics and Informatics JF - Biomedical Statistics and Informatics JO - Biomedical Statistics and Informatics SP - 31 EP - 39 PB - Science Publishing Group SN - 2578-8728 UR - https://doi.org/10.11648/j.bsi.20261101.13 AB - Diabetes is one of the top ten diseases that causes death, and it has become a major concern in many countries, with type 2 diabetes accounting for 96% of diabetes cases. The progression of type 2 diabetes to neuropathy is a complex process influenced by various factors, including glycemic control, duration of diabetes, and individual characteristics. Absorbing chains are one of the applications of Markov chains, which are used to determine how long patients remain in a transient state before they are absorbed. The study objective was to predict the mean sojourn time (average time) that type 2 diabetic patients live with the disease before they enter the absorbed state (i.e., amputation of the limbs or death). Fasting blood sugar levels and neuropathy conditions developed by type 2 diabetic patients were divided into eight states. The states were further classified into transient and absorbing states, where States 1-6 (low FBS, normal FBS, moderate FBS, high FBS, and numbness) formed transient states, and States 7 and 8 were absorbing states (amputation of limbs and death). The results revealed that the average time for patients with a low FBS state to stay with the disease before their limbs are amputated or to die is 14 years, and the average time for those with normal and moderate FBS states is 27 years each. Patients in the high and numbness states have average stay times of 26 and 23 years, respectively, to live with the disease before their limbs are amputated or they die. However, patients in the ulcer state have an average of two years to live with the disease before their limbs are amputated or die. In conclusion, patients’ condition deteriorates gradually as they transition to the complication stage, and patients are more likely to have their limbs amputated or die. VL - 11 IS - 1 ER -